Healthcare
The United Laboratories International Holdings Limited(ULIHF)
Live Price
Offline$1.24
+0.00% today
1Y Change
-32.97%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $16.31B
- Revenue Growth
- -6.5%
- EPS Growth
- -28.1%
- Dividend Yield
- 6.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
The United Laboratories International Holdings Limited (ULIHF) is a Healthcare stock with a market cap of $16.31B and listed on OTC. The stock last traded around $1.24 and down 33.0% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -6.5%, EPS growth of -28.1%, a dividend yield of 6.0%. What stands out right now is revenue -6.5%, EPS -28.1%, free cash flow -35.6% with operating margin 17.3% and ROIC 8.1%. The dividend matters to the case here, with a current yield around 6.0%. Valuation is more restrained than many high-expectation growth names at P/E 11.9 and price/sales 1.2. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ULIHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-6.5% vs +7.6% peer median
Operating Margin
Below sector median
+17.3% vs +19.4% peer median
P/E
Below sector median
11.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Mar 24, 2026 with an EPS surprise of +83.3% and a revenue surprise of +10.1%.
The operating picture looks softer than before
Revenue is at -6.5% and EPS is at -28.1%, with operating margin around 17.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 24, 2026 | +83.3% | -21.8% | -23.5% | -22.4% |
2026 Mar 23, 2026 | โ | +0.0% | -23.5% | -22.4% |
2025 Sep 1, 2025 | -21.7% | +0.0% | +39.0% | +39.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ULIHF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ULIHF Max Drawdown
-47.81%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ULIHF and SPY.
Company Overview
The United Laboratories International Holdings Limited
Other OTC
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
- Leadership
- Hoi Shan Tsoi
- IPO Date
- Nov 3, 2014
- Employees
- 17.0k
- Street Address
- 6 Fuk Wang Street
- Mailing
- Yuen Long
- Region
- Yuen Long, HK
- Reporting Currency
- USD
- Investor Line
- 852 2687 1033
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 11.9
- EV/EBITDA
- 3.5
- Price/Sales
- 1.2
- Price/Book
- 1.4
Growth
- Revenue
- -6.5%
- EPS
- -28.1%
- Free Cash Flow
- -35.6%
Profitability
- Gross Margin
- 41.8%
- Operating Margin
- 17.3%
- Net Margin
- 15.9%
- ROE
- 12.6%
- ROIC
- 8.1%
Balance Sheet
- Debt/Equity
- 0.29
- Current Ratio
- 1.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.